COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01443650
Recruitment Status : Completed
First Posted : September 30, 2011
Last Update Posted : June 28, 2013
Regeneron Pharmaceuticals
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : November 2011
Actual Study Completion Date : November 2011